

『女性てんかんの診療』正誤表

いつも小社出版物をご利用いただき誠にありがとうございます。当該書籍に以下の誤りがございました。深くお詫びするとともに、ここに訂正いたします。

● p.25 10行目

【誤】第3章で扱います

【正】第5章で扱います

● p.40 8行目

【誤】評価はなくなって

【正】評価は少なくなって

● p.40 12～13行目

【誤】「Critical」から「Low」あるいは「No」

【正】「High」から「No」

● p.53 8行目

【誤】◆超低用量

【正】◆低用量

● p.85 表2-4の2018の列, 2行目

【誤】Mostacci

【正】Mostacci (b)

● p.86 表2-5の中央の列, 2行目

【誤】Mostacci

【正】Mostacci (b)

● p.87 1行目

【誤】(CDC)

【正】(CDC 2024)

- p.90 11 行目
【誤】 42 日以内です.
【正】 42 日以内です (WHO 2012).

- p.92 7 行目
【誤】 3.82
【正】 3.42

- p.95 表 2-9, 左から 3 列目, 下から 3 行目
【誤】 85.70%
【正】 85.7%

- p.95 下から 3 行目
【誤】 85%
【正】 87.5%

- p.101 最下行
【誤】 胚移植は
【正】 胚移植の成功率は

- p.102 13 行目
【誤】 Mostacci 2018
【正】 Mostacci 2018a

- p.111 表 3-1, 「北欧」の列, 3 行目
【誤】 Wide (Sweden)
【正】 Wide (a) (Sweden)

- p.111 表 3-1, 「その他の地域」の列, 下から 5 行目
【誤】 Mostacci (Italy)
【正】 Mostacci (b) (Italy)

- p.111 表 3-1, 「北欧」の列, 最下行
【誤】 Christensen (Nordic 5)
【正】 Christensen (a) (Nordic 5)

● p.112 上から 8 行目
【誤】(Christensen 2024)
【正】(Christensen 2024a)

● p.112 下から 2 行目
【誤】(Christensen 2024)
【正】(Christensen 2024a)

● p.114 図 3-1, キャプション下から 2 行目
【誤】トレンドもない
【正】トレンドも少ない

● p.116 表 3-2a, 「著者・報告年」の列, 下から 7 行目
【誤】Meador 2020
【正】Meador 2020b

● p.118 表 3-2b, 「著者・報告年」の列, 下から 2 行目
【誤】Mostacci 2018
【正】Mostacci 2018a

● p.118 表 3-2b, 「著者・報告年」の列, 最下行
【誤】Meador 2020
【正】Meador 2020b

● p.120 表 3-2b, 「著者・報告年」の列, 上から 6 行目
【誤】Bromley 2023
【正】Bromley 2023b

● p.121 上から 6 行目
【誤】Bromley 2023
【正】Bromley 2023a

● p.124 下から 3 行目
【誤】Vajda 2024
【正】Vajda 2024b

- p.128 上から 8 行目
【誤】 (Vajda 2024)
【正】 (Vajda 2024b)
- p.129 上から 5 行目
【誤】 (Vajda 2024)
【正】 (Vajda 2024b)
- p.129 最下行
【誤】 7.9%
【正】 7.96%
- p.129 表 3-3, 「著者・報告年」の列, 上から 3 行目
【誤】 Vajda 2024
【正】 Vajda 2024b
- p.132 表 3-5, 著者の列, 上から 7 行目
【誤】 Wide
【正】 Wide (b)
- p.132 表 3-5, 著者の列, 下から 3 行目
【誤】 Bromley
【正】 Bromley (b)
- p.134 上から 5 行目
【誤】 (Honybun 2024)
【正】 (Honybun 2024a)
- p.134 表 3-6 右下の説明
【誤】 (Honybun 2024 より引用)
【正】 (Honybun 2024a より引用)
- p.135 下から 5 行目
【誤】 (Honybun 2024)
【正】 (Honybun 2024a)

- p.138 最下行
【誤】(Honybun 2024)
【正】(Honybun 2024a)
- p.147 上から 6 行目
【誤】(Christensen 2024)
【正】(Christensen 2024a)
- p.151 上から 12～13 行目
【誤】過去に一時的に効果のあった LEV を
【正】PER を
- p.164 下から 6 行目
【誤】(IQVIA)
【正】(IQVIA 2023)
- p.165 表 3-12, 「論文など」の列, 2 行目
【誤】(Tomson)
【正】(Tomson b)
- p.165 表 3-12, 「論文など」の列, 6 行目
【誤】(Christensen)
【正】(Christensen b)
- p.165 表 3-12, 「論文など」の列, 7 行目
【誤】(Honybun)
【正】(Honybun b)
- p.165 表 3-12, 「結果・コメント」の列, 5 行目
【誤】2023 年, より詳細な
【正】2023 年よりも詳細な
- p.165 下から 6 行目
【誤】(Christensen 2024)
【正】(Christensen 2024b)

- p.165 下から 4 行目
【誤】 (Honybun 2024)
【正】 (Honybun 2024b)

- p.174 上から 9 行目
【誤】 WHO のガイドライン
【正】 WHO のガイドライン (WHO 2015)

- p.176 下から 12 行目
【誤】 (Cueto 2012)
【正】 (Cueto 2016)

- p.179 上から 9～10 行目
【誤】 (Meador 2020)
【正】 (Meador 2020a)

- p.221 下から 3 行目
【誤】 (伊藤 2025)
【正】 (伊藤真也 2025)

- p.221 下から 2 行目
【誤】 2020, 伊藤 2025)
【正】 2020, 伊藤真也 2025)

- p.226 上から 11～12 行目
【誤】 (伊藤 2025)
【正】 (伊藤直樹 2025)

- p.236 下から 6 行目
【誤】 (安井 2012)
【正】 (Yasui 2012)

- p.262 下から 4 行目
【誤】 書いてあります.
【正】 書いてあります (環境省 2020).

『女性てんかんの診療』文献 補訂版

はじめに

- Annegers JF, et al: Remission of seizures and relapse in patients with epilepsy. *Epilepsia*, 20(6): 729–37, 1979.
- 大阪大学大学院人間科学研究科・比較発達心
理学研究室：発達加速現象の研究―第
12 回全国初潮調査結果―，2011.
[https://www.suteteko.net/blog/wp-content/
uploads/2017/07/introduction.pdf](https://www.suteteko.net/blog/wp-content/uploads/2017/07/introduction.pdf)
(2026 年 7 月閲覧)
- 加藤昌明：薬物療法―臨床的解説―. *Pharm
Med*, 36 (8) : 34–8, 2018.
- 加藤昌明：「新規抗発作薬」の特性、役割と使
い方. *日臨*, 80 (12) : 1961–7, 2022.
- 厚生労働省：令和 6 年簡易生命表の概況，
2024. (a)
[https://www.mhlw.go.jp/toukei/saikin/
hw/life/life24/index.html](https://www.mhlw.go.jp/toukei/saikin/hw/life/life24/index.html)
- 厚生労働省：令和 6 年（2024）人口動態統計
月報年計（概数）の概況，2024. (b)
[https://www.mhlw.go.jp/toukei/saikin/
hw/jinkou/geppo/nengai24/index.html](https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai24/index.html)
- 玉田太朗，ほか：本邦女性の閉経年齢. *日産婦
会誌*, 47 (9) : 947–52, 1995.

第 1 章

- Asadi-Pooya AA, et al: Cosmetic adverse ef-
fects of antiseizure medications; A sys-
tematic review. *Seizure*, 91: 9–21, 2021.
- Asadollahi M, et al: Can physiologic menstrual
cycle change serum lamotrigine conce-
ntration? *Seizure*, 33: 35–7, 2015.
- Atif M, et al: The relationship between epi-
lepsy and sexual dysfunction: a review of
the literature. *Springerplus*, 5(1): 2070,
2016.
- Barone JC, et al: A scoping review of hormonal
clinical trials in menstrual cycle-related
brain disorders: Studies in premenstrual
mood disorder, menstrual migraine, and
catamenial epilepsy. *Front Neuroendo-
crinol*, 71: 101098, 2023.
- Berry-Bibee EN, et al: Drug interactions bet-
ween hormonal contraceptives and psy-
chotropic drugs: a systematic review. *Co-
ntraception*, 94(6): 650–67, 2016.
- Bosak M, et al: Menstrual disorders and their
determinants among women with epi-
lepsy. *Neuropsychiatr Dis Treat*, 14:
2657–64, 2018.
- Cagnetti C, et al: Seizure course during pre-
gnancy in catamenial epilepsy. *Neurology*,
83(4): 339–44, 2014.
- Chen B, et al: Cosmetic side effects of antiepi-
leptic drugs in adults with epilepsy. *Epi-
lepsy Behav*, 42: 129–37, 2015.
- Chen LW, et al: Topiramate-associated sexual
dysfunction: A systematic review.

- Epilepsy Behav, 73: 10–7, 2017.
- Christensen J, et al: Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. *Epilepsia*, 48(3): 484–9, 2007.
- Chukwu J, et al: Weight change, genetics and antiepileptic drugs. *Expert Rev Clin Pharmacol*, 7(1): 43–51, 2014.
- Cleland PG: Controlled double-blind crossover study of norethisterone (0.35 mg/day) in the treatment of catamenial exacerbation of epilepsy. *Epilepsia*, 36(Suppl 3): S101, 1995.
- Dana-Haeri J, et al: Effect of norethisterone on seizures associated with menstruation. *Epilepsia*, 24(3): 377–81, 1983.
- Decker BM, et al: Inconsistent reporting of drug-drug interactions for hormonal contraception and antiepileptic drugs -Implications for reproductive health for women with epilepsy. *Epilepsy Behav*, 114(Pt A):107626, 2021.
- Doose DR, et al: Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. *Epilepsia*, 44(4):540–9, 2003.
- Drugs.com: Interactions between Drospirenone and Topiramate Drospirenone + Topiramate: Can You Take Them Together? <https://www.drugs.com/drug-interactions/drospirenone-with-topiramate-4018-0-2216-0.html> (2026 年 7 月閲覧)
- Feely M, et al: Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. *Lancet*, 2(8289): 71–3, 1982.
- Feely M, et al: Intermittent clobazam for catamenial epilepsy: tolerance avoided. *J Neurol Neurosurg Psychiatry*, 47(12): 1279–82, 1984.
- Frank S, et al: A Clinical Approach to Catamenial Epilepsy: A Review. *Perm J*, 24: 1–3, 2020.
- Gelisse P, et al: Dramatic weight loss with levetiracetam. *Epilepsia*, 49(2): 308–15, 2008.
- Gil-Nagel A, et al: Effect of lamotrigine on sexual function in patients with epilepsy. *Seizure*, 15(3): 142–9, 2006.
- Gilad R, et al: Lamotrigine and catamenial epilepsy. *Seizure*, 17(6): 531–4, 2008.
- Guo J, et al: Comparison of the probability of four anticonvulsant mood stabilizers to facilitate polycystic ovary syndrome in women with epilepsies or bipolar disorder-A systematic review and meta-analysis. *Front Psychiatry*, 14:1128011, 2023.
- Harden CL: Sexual dysfunction in women with epilepsy. *Seizure*, 17(2): 131–5, 2008.
- Harden CL, et al: Neuroendocrine consideration in the treatment of men and women with epilepsy. *Lancet Neurol*, 12(1): 72–83, 2013.
- Henning O, et al: Sexual function in people with epilepsy: Similarities and differences with the general population. *Epilepsia*, 60(9): 1984–92, 2019.
- Herzog AG, et al: Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. *Arch Neurol*,

- 43(4):341–6, 1986.
- Herzog AG: Reproductive endocrine considerations and hormonal therapy for women with epilepsy. *Epilepsia*, 32(Suppl 6): S27–33, 1991.
- Herzog AG, et al: Three patterns of catamenialepilepsy. *Epilepsia*, 38(10): 1082 – 8, 1997.
- Herzog AG, et al: Menstrual cycle interval and ovulation in women with localization-related epilepsy. *Neurology*, 57(11): 2133–5, 2001.
- Herzog AG, et al: Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. *Epilepsy Behav*, 4(4): 407–13, 2003.
- Herzog AG, et al: Serum valproate levels with oral contraceptive use. *Epilepsia*, 46(6): 970–1, 2005.
- Herzog AG: Catamenial epilepsy: definition, prevalence pathophysiology and treatment. *Seizure*, 17(2): 151–9, 2008.
- Herzog AG, et al: Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. *Neurology*, 72(10): 911–4, 2009.
- Herzog AG, et al: Variation of seizure frequency with ovulatory status of menstrual cycles. *Epilepsia*, 52(10): 1843–8, 2011.
- Herzog AG, et al: Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. *Neurology*, 78(24): 1959–66, 2012.
- Herzog AG: Catamenial epilepsy: Update on prevalence, pathophysiology and treatment from the findings of the NIH Progesterone Treatment Trial. *Seizure*, 28: 18–25, 2015.
- Hu X, et al: A meta-analysis of polycystic ovarysyndrome in women taking valproate for epilepsy. *Epilepsy Res*, 97(1-2): 73–82, 2011.
- Isojärvi JI, et al: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. *N Engl J Med*, 329(19): 1383–8, 1993.
- Isojärvi JI, et al: Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. *Ann Neurol*, 43(4): 446–51, 1998.
- Isojärvi JI, et al: Altered ovarian function and cardiovascular risk factors in valproate-treated women. *Am J Med*, 111(4): 290–6, 2001.
- Isojärvi JI, et al: Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. *CNS Drugs*, 19(3): 207–23, 2005.
- Kaufman KR, et al: Epilepsy and AED-induced decreased libido - The unasked psychosocial comorbidity. *Epilepsy Behav*, 52(Pt A): 236–8, 2015.
- King A, et al: Contraceptive vaginal ring reduces lamotrigine levels. *Epilepsy Behav*, 111:107162, 2020.
- Kumar DP, et al: Study of Sexual Dysfunction in People Living with Epilepsy at a Tertiary Care Center of South India. *Neurol India*, 68(4):861–6, 2020.
- Lazorwitz A, et al: Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. *Obstet Gynecol*, 139(4): 579–87, 2022.

- Li Q, et al: Hormonal Changes in Women with Epilepsy. *Neuropsychiatr Dis Treat*, 20: 373–88, 2024.
- Li S, et al: Research Progress on the Effect of Epilepsy and Antiseizure Medications on PCOS Through HPO Axis. *Front Endocrinol (Lausanne)*, 12: 787854, 2021.
- Lim LL, et al: Acetazolamide in women with catamenial epilepsy. *Epilepsia*, 42(6): 746–9, 2001.
- Lossius MI, et al: Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy-a prospective randomized double-blind withdrawal study. *Epilepsia*, 48(10): 1875–82, 2007.
- Maguire MJ, et al: Treatments for seizures in catamenial (menstrual-related) epilepsy. *Cochrane Database Syst Rev*, 9(9): CD013225, 2021.
- Martin CK, et al: Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. *J Psychopharmacol*, 23(7): 814–25, 2009.
- McAuley JW, et al: A Pilot Study of the Neurosteroid Ganaxolone in Catamenial Epilepsy: Clinical Experience in Two Patients. *Epilepsia*, 42(Suppl 7): 85, 2001.
- Mikkonen K, et al: Long-term reproductive endocrine health in young women with epilepsy during puberty. *Neurology*, 62(3): 445–50, 2004.
- Morrell MJ, et al: Reproductive disturbances in patients with epilepsy. *Cleve Clin J Med*, 71(Suppl 2): S19–24, 2004.
- Morrell MJ, et al: Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. *Epilepsy Behav*, 6(3): 360–5, 2005.
- Moseley BD, et al: A review of the drug-drug interactions of the antiepileptic drug brivaracetam. *Epilepsy Res*, 163: 106327, 2020.
- Najafi M, et al: Progesterone therapy in women with intractable catamenial epilepsy. *Adv Biomed Res*, 2: 8, 2013.
- Nayyar AS, et al: A study on gingival enlargement and folic acid levels in phenytoin-treated epileptic patients: Testing hypotheses. *Surg Neurol Int*, 4: 133, 2013.
- Noai M, et al: Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. *Acta Neurol Scand*, 133(3):216–23, 2016.
- Nucera B, et al: Progesterone and its derivatives for the treatment of catamenial epilepsy: A systematic review. *Seizure*, 109: 52–9, 2023.
- Ogunjimi L, et al: Polycystic ovarian syndrome in Nigerian women with epilepsy on carbamazepine/levetiracetam monotherapy. *Acta Neurol Scand*, 143(2): 146–53, 2021.
- Ogunjimi L, et al: Differential effects of carbamazepine and levetiracetam monotherapy on reproductive endocrine function in Nigerian women with epilepsy. *Heliyon*, 9(9): e20098, 2023.
- Pellinen J, et al: The impact of medications and medical comorbidities on sexual function in people with epilepsy. *Epilepsy*

- Res, 172: 106596, 2021.
- Pickrell WO, et al: Weight change associated with antiepileptic drugs. *J Neurol Neurosurg Psychiatry*, 84(7): 796–9, 2013.
- Rathore C, et al: Prevalence and Diagnosis of Sexual Dysfunction in People with Epilepsy. *Neurol Clin*, 40(4): 869–89, 2022.
- Rauchenzauner M, et al: Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy-Role of progestins. *Seizure*, 74: 89–92, 2020.
- Reddy DS: Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women. *J Neuroendocrinol*, 34(2): e13028, 2022.
- Reimers A: Contraception for women with epilepsy: counseling, choices, and concerns. *Open Access J Contracept*, 7: 69–76, 2016.
- Rissardo JP, et al: Antiseizure Medication-Induced Alopecia: A Literature Review. *Medicines (Basel)*, 10(6): 35, 2023.
- Rosenfeld WE, et al: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. *Epilepsia*, 38(3): 317–23, 1997.
- Santos AMC, et al: Sexual function in women of fertile age with epilepsy. *Epilepsy Behav*, 125: 108399, 2021.
- Sidhu J, et al: The pharmacokinetic and pharmacodynamic consequences of the coadministration of lamotrigine and a combined oral contraceptive in healthy female subjects. *Br J Clin Pharmacol*, 61(2): 191–9, 2006.
- Sidhu HS, et al: Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study. *Epilepsy Res*, 139: 20–7, 2018.
- Stockis A, et al: Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. *J Clin Pharmacol*, 53(12): 1313–21, 2013.
- Stockis A, et al: Interaction between brivaracetam(100mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. *Epilepsia*, 55(3): e27–31, 2014.
- Svalheim S, et al: Do women with epilepsy have increased frequency of menstrual disturbances? *Seizure*, 12(8): 529–33, 2003.
- Svalheim S, et al: Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. *Epilepsy Behav*, 16(2): 281–7, 2009.
- Svalheim S, et al: Interactions between antiepileptic drugs and hormones. *Seizure*, 28: 12–7, 2015.
- Tolbert D, et al: A Comprehensive Overview of the Clinical Pharmacokinetics of Clonazepam. *J Clin Pharmacol*, 59(1): 7–19, 2019.
- Trevisol-Bittencourt PC, et al: Phenytoin as the first option in female epileptic patients? *Arq Neuropsiquiatr*, 57(3B): 784–6,

- 1999.
- Vadlamudi L, et al: Insights into neurosteroids and their role in women with epilepsy. *Front Glob Womens Health*, 5: 1363470, 2024.
- Vélez-Ruiz NJ, et al: Issues for Women with Epilepsy. *Neurol Clin*, 34(2): 411–25, ix, 2016.
- Wegner I, et al: Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. *Neurology*, 73(17): 1388–93, 2009.
- Yeo E, et al: Catamenial Epilepsy. *Practical Neurology*, October: 35–9, 44, 2022.
- Zhao S, et al: Association between epilepsy and risk of sexual dysfunction: A meta-analysis. *Seizure*, 65: 80–8, 2019.
- Zhao S, et al: Association between epilepsy and risk of sexual dysfunction: A meta-analysis. *Seizure*, 65: 80–8, 2019.
- 日本産科婦人科学会：多嚢胞性卵巣症候群に関する全国症例調査の結果と本邦における新しい診断基準(2024)について, 2024. <https://www.jsog.or.jp/medical/5122/>
- フィコンパ®インタビューフォーム. 改訂第8版, pp.51–3, 2025.

第2章

- Abdulrazaq AA, et al: Seizure control in women with epilepsy undergoing assisted reproductive technology. *Epilepsia*, 64(10): e207–13, 2023.
- Adab N, et al: The longer term outcome of children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry*, 75(11): 1575–83, 2004.
- Artama M, et al: Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. *Am J Epidemiol*, 159(11): 1057–63, 2004.
- Baker GA, et al: Experiences of women of childbearing age with epilepsy throughout their motherhood journey: Results from a social media listening study. *Epilepsy Behav*, 174: 110799, 2026.
- Bardy AH: Incidence of seizures during pregnancy, labor and puerperium in epileptic women: a prospective study. *Acta Neurol Scand*, 75: 356–60, 1987.
- Bech BH, et al: Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. *BMJ*, 349: g5159, 2014.
- Berry-Noronha A, et al: Risk of Adverse Pregnancy Outcomes Associated With Anti-seizure Medications and Their Indications: A Systematic Review and Meta-Analysis. *Neurology*, 104(3): e210233, 2025.
- Cagnetti C, et al: Seizure course during pregnancy in catamenial epilepsy. *Neurology*, 83(4): 339–44, 2014.
- CDC : Identifying Severe Maternal Morbidity (SMM) in Maternal Infant Health <https://www.cdc.gov/maternal-infant-health/php/severe-maternal-morbidity/icd.html> (Accessed at 2026/7/19)

- Chin RF, et al: Outcomes of childhood epilepsy at age 33 years: a population-based birth-cohort study. *Epilepsia*, 52(8): 1513–21, 2011.
- Christensen J, et al: Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. *Lancet*, 373(9669): 1105–10, 2009.
- Christensen J: The Epidemiology of Posttraumatic Epilepsy. *Semin Neurol*, 35(3): 218–22, 2015.
- Christensen J, et al: Maternal death in women with epilepsy: Smaller scope studies. *Neurology*, 91(18): e1716–20, 2018.
- Christensen J, et al: Prevalence of epilepsy: a population-based cohort study in Denmark with comparison to Global Burden of Disease (GBD) prevalence estimates. *J Neurol Neurosurg Psychiatry*, 96(5): 480–8, 2025.
- Cockerell OC, et al: Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. *Epilepsia*, 38(1): 31 – 46, 1997.
- Creanga AA, et al: Pregnancy-Related Mortality in the United States, 2011-2013. *Obstet Gynecol*, 130(2): 366–73, 2017.
- Dahl-Hansen E, et al: Epilepsy at different ages-Etiologies in a Norwegian population. *Epilepsia Open*, 4(1): 176–81, 2018.
- Danielsson KC, et al: Maternal complications in pregnancy and childbirth for women with epilepsy: Time trends in a nationwide cohort. *PLoS One*, 14(11): e0225334, 2019.
- Decker BM, et al: A nationwide analysis of maternal morbidity and acute postpartum readmissions in women with epilepsy. *Epilepsy Behav*, 117: 107874, 2021.
- Dreier JW, et al: Epilepsy risk in offspring of affected parents; a cohort study of the "maternal effect" in epilepsy. *Ann Clin Transl Neurol*, 8(1): 153–62, 2021.
- Edey S, et al: SUDEP and epilepsy-related mortality in pregnancy. *Epilepsia*, 55(7): e72–4, 2014.
- Eriksson H, et al: Family history increases the risk of late seizures after stroke. *Neurology*, 93(21): e1964–70, 2019.
- Fairgrieve SD, et al: Population based, prospective study of the care of women with epilepsy in pregnancy. *BMJ*, 321(7262): 674–5, 2000.
- Farmen AH, et al: Age-specific birth rates in women with epilepsy: a population-based study. *Brain Behav*, 6(8): e00492, 2016.
- Farmen AH, et al: Increased rate of acute caesarean sections in women with epilepsy: results from the Oppland Perinatal Database in Norway. *Eur J Neurol*, 26(4): 617–23, 2019.
- Forbes H, et al: First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study. *J Neurol Neurosurg Psychiatry*, 95(8): 693–703, 2024.
- GBD 2016 Epilepsy Collaborators: Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the

- Global Burden of Disease Study 2016. *Lancet Neurol*, 18(4): 357–75, 2019.
- Gjerde IO, et al: The course of epilepsy during pregnancy: a study of 78 cases. *Acta Neurol Scand*, 78: 198–205, 1988.
- Graham NS, et al: Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register. *Stroke*, 44(3): 605–11, 2013.
- Griffiths D, et al: Epidemiology and etiology of young stroke. *Stroke Res Treat*, 2011: 209370, 2011.
- Gyamfi-Bannerman C, et al: Maternal morbidity and mortality associated with epilepsy. *J Matern Fetal Neonatal Med*, 35(25): 7917–23, 2022.
- Han SH, et al: Trends of childbirth and cesarean section among women with epilepsy in Korea. *Epilepsy Behav*, 164: 110248, 2025.
- Harden C, et al: Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*, 88(17): 1674–80, 2017.
- Hauser WA, et al: Mortality in patients with epilepsy. *Epilepsia*, 21(4): 399–412, 1980.
- Helbig KL, et al: Genetic risk perception and reproductive decision making among people with epilepsy. *Epilepsia*, 51(9): 1874–7, 2010.
- Huang CY, et al: Clinical characteristics and outcomes in pregnant women with epilepsy. *Epilepsy Behav*, 112: 107433, 2020.
- ILAE : International League Against Epilepsy Consortium on Complex Epilepsies: GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. *Nat Genet*, 55(9): 1471–82, 2023.
- Jiménez M, et al: Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. *Neurologia (Engl Ed)*, 38(2):106-13, 2023.
- Kaneko S: Pregnancy and quality of life in women with epilepsy. *Clin Ther*, 20 (Suppl A): A30–47, 1998.
- Kapoor D, et al: Trends in maternal deaths from epilepsy in the United Kingdom: a 30-year retrospective review. *Obstet Med*, 7(4): 160–4, 2014.
- Kariuki JG, et al: Fertility rate of epileptic women at Kenyatta National Hospital. *East Afr Med J*, 85(7): 341–6, 2008.
- Kuang H, et al: Reproductive and fetal outcomes in women with epilepsy: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*, 37(1): 2351196, 2024.
- Kuo CY, et al: The impact of epilepsy and antiseizure medications on pregnancy and neonatal outcomes: A nationwide cohort study. *Brain Behav*, 13(12): e3287, 2023.
- Langan Y, et al: The incidence of sudden unexpected death in epilepsy (SUDEP) in the Republic of Ireland. *Seizure*, 122: 34–8, 2024.
- Larsen MD, et al: The efficacy of assisted

- reproductive treatment in women with epilepsy. *Reprod Biomed Online*, 41(6): 1015–22, 2020.
- Li S, et al: Epilepsy in China: Factors influencing marriage status and fertility. *Seizure*, 71: 179–84, 2019.
- Löfgren E, et al: Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility. *Epilepsy Behav*, 14(1): 102–7, 2009.
- MacDonald SC, et al: Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. *JAMA Neurol*, 72(9): 981–8, 2015.
- MacEachern DB, et al: Infertility, impaired fecundity, and live birth/pregnancy ratio in women with epilepsy in the USA: Findings of the Epilepsy Birth Control Registry. *Epilepsia*, 60(9): 1993–8, 2019.
- Margolese N, et al: Maternal epilepsy and pregnancy, delivery and neonatal outcomes: A population-based retrospective cohort study. *Epilepsy Behav*, 163: 110221, 2025.
- Mazzone PP, et al: Comparison of Perinatal Outcomes for Women With and Without Epilepsy: A Systematic Review and Meta-analysis. *JAMA Neurol*, 80(5): 484–94, 2023.
- Mazzone PP, et al: Association of maternal epilepsy with perinatal outcomes, and an exploration of prenatal antiseizure medication: A population-based retrospective cohort study. *Epilepsia*, 66(9): 3353–68, 2025.
- MBRRACE-UK : Saving Lives, Improving Mothers' Care 2017 -Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-15. 2017.
<https://www.npeu.ox.ac.uk/mbrrace-uk/reports/maternal-reports/maternal-report-2013-2015>
- MBRRACE-UK : Saving Lives, Improving Mothers' Care 2020 -Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016-18. 2020.
<https://www.npeu.ox.ac.uk/mbrrace-uk/reports/maternal-reports/maternal-report-2016-2018>
- MBRRACE-UK : Saving Lives, Improving Mothers' Care 2023 -Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2019-21. 2023.
<https://www.npeu.ox.ac.uk/mbrrace-uk/reports/maternal-reports/maternal-report-2019-2021>
- McElrath TF, et al: The Obstetrical Care and Delivery Experience of Women with Epilepsy in the MONEAD Study. *Am J Perinatol*, 41(7): 935–43, 2024.
- Mohammadi B, et al: The intersection of epilepsy and assisted reproduction: A review of therapeutic approaches and considerations. *Seizure*, 133: 219–23, 2025.
- Moon HJ, et al: Premature Mortality and

- Causes of Death Among People With Epilepsy: A Nationwide Population-Based Incident Cohort Study. *Neurology*, 100(20): e2060–70, 2023.
- Mostacci B, et al: Estrogen-related seizure exacerbation following hormone therapy for assisted reproduction in women with epilepsy. *Seizure*, 61: 200–2, 2018. (a)
- Mostacci B, et al: Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. *J Neurol Neurosurg Psychiatry*, 89(9): 983–88, 2018. (b)
- Nilsson L, et al: Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. *Epilepsia*, 38(10): 1062 – 8, 1997.
- Olafsson E, et al: Fertility in patients with epilepsy: a population-based study. *Neurology*, 51(1): 71–3, 1998.
- Panelli DM, et al: Association of Epilepsy and Severe Maternal Morbidity. *Obstet Gynecol*, 138(5): 747–54, 2021.
- Peljto AL, et al: Familial risk of epilepsy: a population-based study. *Brain*, 137(Pt3): 795–805, 2014.
- Pennell PB, et al: Fertility and Birth Outcomes in Women With Epilepsy Seeking Pregnancy. *JAMA Neurol*, 75(8): 962–9, 2018.
- Perlman NC, et al: Examining the Joint Effects of Epilepsy and Mental Health Conditions on Severe Maternal Morbidity. *J Womens Health (Larchmt)*, 34(3): e426, 2025.
- Perucca P, et al: Genetic Contributions to Acquired Epilepsies. *Epilepsy Curr*, 21(1): 5–13, 2021.
- Razaz N, et al: Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy. *JAMA Neurol*, 74(8): 983–91, 2017.
- Razaz N, et al: Risk of Perinatal and Maternal Morbidity and Mortality Among Pregnant Women With Epilepsy. *JAMA Neurol*, 81(9): 985–95, 2024.
- Richards N, et al: Antiepileptic drug exposure in pregnancy and pregnancy outcome from national drug usage data. *BMC Pregnancy Childbirth*, 18(1): 84, 2018.
- Snowden JM, et al: Severe Maternal Morbidity: A Comparison of Definitions and Data Sources. *Am J Epidemiol*, 190(9): 1890–7, 2021.
- Starck C, et al: Fertility and marital status in adults with childhood onset epilepsy: A population-based cohort study. *Epilepsia*, 60(7): 1438–44, 2019.
- Sveinsson O, et al: Clinical risk factors in SUDEP: A nationwide population-based case-control study. *Neurology*, 94(4): e419–29, 2020.
- Tanaka H, et al: Maternal Death Related to Sudden Unexpected Death in Epilepsy: A Nationwide Survey in Japan. *Brain Sci*, 11(8): 995, 2021.
- Tomson T, et al: Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. *Epilepsia*, 35: 122–30, 1994.

- Vajda FJE, et al: Cesarean section in Australian women with epilepsy. *Epilepsy Behav*, 89: 126–9, 2018.
- Van Marter LJ, et al: Neonatal Outcomes in the MONEAD Study of Pregnant Women with Epilepsy. *J Pediatr* X, 7: 100073, 2021.
- Verducci C, et al: SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies. *Neurology*, 93(3): e227–36, 2019.
- Viale L, et al: Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. *Lancet*, 386(10006): 1845–52, 2015.
- Viinikainen K, et al: Fertility in women with active epilepsy. *Neurology*, 69(22): 2107–8, 2007.
- Wallace H, et al: Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. *Lancet*, 352(9145): 1970 – 3, 1998.
- WHO : The WHO Application of ICD-10 to deaths during pregnancy, childbirth and the puerperium: ICD-MM. 2012. <https://iris.who.int/server/api/core/bitstreams/1bbeb2a8-e4c0-46c8-aa0d-0056627a17b5/content> (Accessed at 2026/7/19)
- Winawer MR, et al: Genetic epidemiology of epilepsy or what do we tell families? *Epilepsia*, 46(Suppl 10): 24–30, 2005.
- Winqvist S, et al: Traumatic brain injuries in children and young adults: a birth cohort study from northern Finland. *Neuroepidemiology*, 29(1-2): 136–42, 2007.
- Yucel A, et al: Maternal deaths with epilepsy: A population-based study in Turkey. *Eur J Obstet Gynecol Reprod Biol*, 258: 33–7, 2021.
- 加藤昌明：てんかんを持つ患者へのプレコンセプションケア. *精神科治療学*, 38 : 555-61, 2023.
- ユニセフ：世界子供白書 2024. 母親と新生児の健康指標, 2024.
https://www.unicef.or.jp/sowc/pdf/UNICEF_SOWC_2024_table3.pdf

第3章

- Adab N, et al: The longer term outcome of children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry*, 75: 1575–83, 2004.
- Almgren M, et al: Population-based study of antiepileptic drug exposure in utero influence on head circumference in newborns. *Seizure*, 18(10): 672–5, 2009.

- Alvestad S, et al: Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study. *Neurology*, 99(6): e605–e615, 2022.
- Andrade C, et al: Gestational Exposure to Valproate and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring: Systematic Review and Meta-Analysis. *Acta Psychiatr Scand*, 151(6): 668–79, 2025.
- Angus-Leppan H, et al: New valproate regulations, informed choice and seizure risk. *J Neurol*, 271(8): 5671–86, 2024.
- Artama M, et al: Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. *Neurology*, 64: 1874–8, 2005.
- Artama M, et al: Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. *Drug Saf*, 36(5): 359–69, 2013.
- Asadi-Pooya A, et al: Effects of carbamazepine on semen parameters in men with newly diagnosed epilepsy. *Iran J Neurol*, 14(3): 168–70, 2015.
- Baker GA, et al: IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study. *Neurology*, 84: 382–90, 2015.
- Ban L, et al: Congenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort Study. *PLoS One*, 10(7): e0131130, 2015.
- Barroso FV, et al: Perinatal outcomes from the use of antiepileptic drugs during pregnancy: a case-control study. *J Matern Fetal Neonatal Med*, 28(12): 1445–50, 2015.
- Battino D, et al: Risk of Major Congenital Malformations and Exposure to Anti-seizure Medication Monotherapy. *JAMA Neurol*, 81(5): 481–89, 2024.
- Bergman JEH, et al: Updated EUROCAT guidelines for classification of cases with congenital anomalies. *Birth Defects Res*, 116(2): e2314, 2024.
- Berkovic SF, et al: Restricting valproate prescribing in men: wisdom or folly? *Pract Neurol*, 24(3): 178–79, 2024.
- Berry RJ, et al: Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. *N Engl J Med*, 341(20): 1485–90, 1999.
- Betts T, et al: Proactive pre-conception counselling for women with epilepsy-is it effective? *Seizure*, 8(6): 322–7, 1999.
- Biale Y, et al: Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. *Eur J Obstet Gynecol Reprod Biol*, 18(4): 211–6, 1984.
- Bjørk M, et al: Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In

- Utero. *JAMA Neurol*, 75(2): 160–68, 2018.
- Bjørk MH, et al: Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. *JAMA Neurol*, 79: 672–81, 2022.
- Blotière PO, et al: Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. *BMJ Open*, 10(6): e034829, 2020.
- Borthen I, et al: Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. *BJOG*, 118(8): 956–65, 2011.
- Bortolus R, et al: Efficacy of 4.0 mg versus 0.4 mg Folic Acid Supplementation on the Reproductive Outcomes: A Randomized Controlled Trial. *Nutrients*, 13(12): 4422, 2021.
- Bromley RL, et al: Early cognitive development in children born to women with epilepsy: a prospective report. *Epilepsia*, 51: 2058–65, 2010.
- Bromley RL, et al: The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. *J Neurol Neurosurg Psychiatry*, 84: 637–43, 2013.
- Bromley RL, et al: Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. *Neurology*, 87: 1943–53, 2016.
- Bromley R, et al: Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*, 8(8): CD010224, 2023. (a)
- Bromley RL, et al: Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. *Epilepsia*, 64(9): 2454–71, 2023. (b)
- Burdge GC, et al: Folic acid supplementation in pregnancy: Are there devils in the detail? *Br J Nutr*, 108(11): 1924–30, 2012.
- Campbell E, et al: Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. *J Neurol Neurosurg Psychiatry*, 85(9): 1029–34, 2014.
- Canger R, et al: Malformations in offspring of women with epilepsy: a prospective study. *Epilepsia*, 40: 1231–6, 1999.
- Chatzi L, et al: Effect of high doses of folic acid supplementation in early pregnancy on child neurodevelopment at 18 months of age: the mother-child cohort 'Rhea' study in Crete, Greece. *Public Health Nutr*, 15(9): 1728–36, 2012.
- Chen D, et al: Effect of epilepsy in pregnancy on fetal growth restriction: a systematic review and meta-analysis. *Arch Gynecol Obstet*, 296(3): 421–7, 2017.
- Chen H, et al: Neurodevelopmental effects of maternal folic acid supplementation: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr*, 63(19): 3771–87, 2023.

- Chen MY, et al: Defining the plasma folate concentration associated with the red blood cell folate concentration threshold for optimal neural tube defects prevention: a population-based, randomized trial of folic acid supplementation. *Am J Clin Nutr*, 109(5): 1452–61, 2019.
- Chen SS, et al: Effects of antiepileptic drugs on sperm motility of normal controls and epileptic patients with long-term therapy. *Epilepsia*, 33(1): 149–53, 1992.
- Chen YH, et al: Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. *Arch Neurol*, 66(8): 979–84, 2009.
- Christensen J, et al: Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*, 309: 1696–703, 2013.
- Christensen J, et al: Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring. *JAMA Netw Open*, 2(1): e186606, 2019.
- Christensen J, et al: Prenatal exposure to antiepileptic medications and fetal growth: a population-based cohort study from the Nordic countries. *Lancet Reg Health Eur*, 38: 100849, 2024. (a)
- Christensen J, et al: Valproate Use During Spermatogenesis and Risk to Offspring. *JAMA Netw Open*, 7(6): e2414709, 2024. (b)
- Christensen J, et al: Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During Spermatogenesis. *JAMA Netw Open*, 8(5): e2512139, 2025.
- Christensen J, et al: Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis: a living meta-analysis-version 1. *J Neurol Neurosurg Psychiatry*, jnnp-2026-338454, 2026.
- Cohen JM, et al: Comparative Safety of Antiepileptic Medication Monotherapy for Major Malformations. *Ann Neurol*, 93(3): 551–62, 2023.
- Cohen JM, et al: Comparative Risk of Major Congenital Malformations With Anti-seizure Medication Combinations vs Valproate Monotherapy in Pregnancy. *Neurology*, 102(2): e207996, 2024.
- Colas S, et al: Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring. *JAMA Netw Open*, 8(11): e2542581, 2025.
- Compañ Gabucio LM, et al: The Use of Lower or Higher Than Recommended Doses of Folic Acid Supplements during Pregnancy Is Associated with Child Attentional Dysfunction at 4-5 Years of Age in the INMA Project. *Nutrients*, 13(2): 327, 2021.
- Coste J, et al: Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. *Sci Rep*, 10:17362, 2020.

- Cueto HT, et al: Folic acid supplementation and fecundability: a Danish prospective cohort study. *Eur J Clin Nutr*, 70(1): 66–71, 2016.
- Cummings C, et al: Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. *Arch Dis Child*, 96: 643–7, 2011.
- Cunnington MC, et al: Final results from 18 years of the International Lamotrigine Pregnancy Registry. *Neurology*, 76(21): 1817–23, 2011.
- Czeizel AE, et al: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med*, 327(26): 1832–5, 1992.
- Czeizel AE: Prevention of congenital abnormalities by periconceptional multivitamin supplementation. *BMJ*, 306(6893): 1645–8, 1993.
- Damkier P, et al: Drifting Too Far From Shore: Paternal Valproate Statement by the European Medicines Agency (EMA). *Pharmacoepidemiol Drug Saf*, 33(10): e70016, 2024.
- Dansky LV, et al: Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. *Ann Neurol*, 21(2): 176–82, 1987.
- Daugaard CA, et al: Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. *JAMA Netw Open*, 3: e2025570, 2020.
- Dreier JW, et al: Prenatal Exposure to Anti-seizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. *JAMA Neurol*, 80: 568–77, 2023.
- Dudukina E, et al: Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries. *Drug Saf*, 46: 661–75, 2023.
- Dwyer ER, et al: Who should consume high-dose folic acid supplements before and during early pregnancy for the prevention of neural tube defects? *BMJ*, 377: e067728, 2022.
- Elkjær LS, et al: Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children. *JAMA Neurol*, 75: 663–71, 2018.
- EMA (European Medicines Agency): EMA/612389/2014. 10 October 2014. PRAC recommends strengthening the restrictions on the use of valproate in women and girls. <https://www.ema.europa.eu/en/news/prac-recommends-strengthening-restrictions-use-valproate-women-girls>. (Accessed at 2026/8)
- EMA (European Medicines Agency): EMA/145600/2018. 23 March 2018. <https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy>

- endorsed_en.pdf (Accessed at 2026/8)
EMA (European Medicines Agency): EMA/334781/2024: PRAC non-interventional imposed PASS final study report assessment report: Valproate and related substances (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium). Procedure no.: EMEA/H/N/PSR/J/0043. https://www.ema.europa.eu/system/files/documents/other/emea-h-n-psr-j-0043-epar_en_0.pdf (Accessed at 2026/8)
- Farmen AH, et al: Intrauterine growth retardation in fetuses of women with epilepsy. *Seizure*, 28: 76–80, 2015.
- Farmen AH, et al: Increased rate of acute caesarean sections in women with epilepsy: results from the Oppland Perinatal Database in Norway. *Eur J Neurol*, 26(4): 617–23, 2019.
- Forsberg L, et al: School performance at age 16 in children exposed to antiepileptic drugs in utero a population-based study. *Epilepsia*, 52: 364–9, 2011.
- Fujii H, et al: Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. *Neurology*, 80(17): 1565–70, 2013.
- Gaily E, et al: Normal intelligence in children with prenatal exposure to carbamazepine. *Neurology*, 62: 28–32, 2004.
- Garey JD, et al: Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated. *Birth Defects Res*, 116(8): e2392, 2024.
- Gaskins AJ, et al: Maternal prepregnancy folate intake and risk of spontaneous abortion and stillbirth. *Obstet Gynecol*, 124(1): 23–31, 2014.
- Gopinath N, et al: Children (10–12 years age) of women with epilepsy have lower intelligence, attention and memory: Observations from a prospective cohort case control study. *Epilepsy Res*, 117: 58–62, 2015.
- Gorjipour F, et al: Serum level of homocysteine, folate and vitamin-B12 in epileptic patients under carbamazepine and sodium valproate treatment: a systematic review and meta-analysis. *Iran Red Crescent Med J*, 15(3): 249–53, 2013.
- Guttuso T Jr, et al: Gabapentin use in hyperemesis gravidarum: a pilot study. *Early Hum Dev*, 86: 65–6, 2010.
- Hao L, et al: Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial. *Am J Clin Nutr*, 88(2): 448–57, 2008.
- Hao N, et al: Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study. *Epilepsia*, 66(5): 1573–84, 2025.
- Hayashi T, et al: Asthenozoospermia: possible association with long-term exposure to an anti-epileptic drug of carbamazepine. *Int J Urol*, 12(1): 113–4, 2005.

- Hernández-Díaz S, et al: Comparative safety of antiepileptic drugs during pregnancy. *Neurology*, 78: 1692–9, 2012.
- Hernández-Díaz S, et al: Association between topiramate and zonisamide use during pregnancy and low birth weight. *Obstet Gynecol*, 123(1): 21–8, 2014.
- Hernández-Díaz S, et al: Fetal growth and premature delivery in pregnant women on antiepileptic drugs. *Ann Neurol*, 82(3): 457–65, 2017.
- Hernández-Díaz S, et al: Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure. *N Engl J Med*, 390(12): 1069–79, 2024.
- Hernandez-Diaz S, et al: Use of Antiseizure Medications Early in Pregnancy and the Risk of Major Malformations in the Newborn. *Neurology*, 105(3): e213786, 2025.
- Hiraoka M, et al: Gene-nutrient and gene-gene interactions of controlled folate intake by Japanese women. *Biochem Biophys Res Commun*, 316(4): 1210–6, 2004.
- Holmes LB, et al: Ascertainment of malformations in pregnancy registries: Lessons learned in the North American AED Pregnancy Registry. *Birth Defects Res*, 115: 1274–83, 2023.
- Honybun E, et al: Neurodevelopmental and Functional Outcomes Following In Utero Exposure to Antiseizure Medication: A Systematic Review. *Neurology*, 102(8): e209175, 2024. (a)
- Honybun E, et al: Paternal exposure to anti-seizure medications and offspring outcomes: a systematic review. *J Neurol Neurosurg Psychiatry*, 96(1): 15–25, 2024. (b)
- Huber-Mollema Y, et al: Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. *Epilepsia*, 60: 1069–82, 2019.
- Hunt S, et al: Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. *Neurology*, 71(4): 272–6, 2008.
- Husebye ESN, et al: Verbal abilities in children of mothers with epilepsy: Association to maternal folate status. *Neurology*, 91(9): e811–e821, 2018.
- Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. *BJOG*, 107(7): 896–902, 2000.
- IQVIA : Valproate EU consortium: A post-authorisation safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring – a population-based retrospective study. Updated Abstract Following Reanalysis of Norway Data Corrigendum to Final Study Report Version 1.1 and Addendum Version 2.0. Stand Alone Abstract V2.0. 2 October 2023.

- https://catalogues.ema.europa.eu/system/files/2024-02/Valproate_PASS_Abstract_V2.0_0.pdf (Accessed at 2026/8)
- Isojärvi JI, et al: Effect of epilepsy and antiepileptic drugs on male reproductive health. *Neurology*, 62(2): 247–53, 2004.
- Jentink J, et al: Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? *Pharmaco-epidemiol Drug Saf*, 19(8): 803–7, 2010.
- JRAP : Japan Registry of Antiepileptic Drugs and Pregnancy.
<https://square.umin.ac.jp/JRAP/index.html> (accessed 2026-08-19)
- Julvez J, et al: Maternal use of folic acid supplements during pregnancy and four-year-old neurodevelopment in a population-based birth cohort. *Paediatr Perinat Epidemiol*, 23(3): 199–206, 2009.
- Kaaja E, et al: Major malformations in offspring of women with epilepsy. *Neurology*, 60(4): 575–9, 2003.
- Källén B, et al: The use of central nervous system active drugs during pregnancy. *Pharmaceuticals (Basel)*, 6(10): 1221–86, 2013.
- Kaneko S, et al: Congenital malformations due to antiepileptic drugs. *Epilepsy Res*, 33(2–3): 145–58, 1999.
- Keni RR, et al: Teratogenicity of antiepileptic dual therapy: Dose-dependent, drug-specific, or both? *Neurology*, 90(9): e790–e796, 2018.
- Kennedy D, et al: Identifying women who might benefit from higher doses of folic acid in pregnancy. *Can Fam Physician*, 58(4): 394–7, 2012.
- Kilic D, et al: Birth outcomes after prenatal exposure to antiepileptic drugs--a population-based study. *Epilepsia*, 55(11): 1714–21, 2014.
- Kinney MO, et al: Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations. *J Neurol Neurosurg Psychiatry*, 89(12): 1320–23, 2018.
- Kjaer D, et al: Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. *BJOG*, 115(1): 98–103, 2008.
- Knight R, et al: Adaptive behaviour in children exposed to topiramate in the womb: An observational cohort study. *Seizure*, 105: 56–64, 2023.
- Kondo A, et al: Dietary folate intakes and effects of folic acid supplementation on folate concentrations among Japanese pregnant women. *J Obstet Gynaecol Res*, 37(4): 331–6, 2011.
- Kose-Ozlece H, et al: Alterations in semen parameters in men with epilepsy treated with valproate. *Iran J Neurol*, 14(3): 164–7, 2015.
- Lacey AS, et al: Educational attainment of children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry*, 89: 736–40, 2018.
- Lattanzi S, et al: Lacosamide during pregnancy and breastfeeding. *Neurol*

- Neurochir Pol, 51: 266–9, 2017.
- Lavu A, et al: Antiseizure medication use during pregnancy and neonatal growth outcomes: A systematic review and meta-analysis. *Br J Clin Pharmacol*, 90(8): 1827–37, 2024.
- Levine SZ, et al: Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring. *JAMA Psychiatry*, 75(2): 176–84, 2018.
- Li R, et al: Pregnancy characteristics and adverse outcomes in offspring of women with epilepsy: a prospective registry study from Mainland China. *Front Neurol*, 14: 1195003, 2023.
- Li Y, et al: Folate supplement dosage for pregnant people with epilepsy: Survey of international experts recommendation and current practices. *Epileptic Disord*, 27(6): 1209–16, 2025.
- Liu C, et al: Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis. *Arch Gynecol Obstet*, 298(4): 697–704, 2018.
- Madley-Dowd P, et al: Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. *Nat Commun*, 15(1): 9640, 2024.
- Margulis AV, et al: Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. *PLoS One*, 14(8): e0214180, 2019.
- Mawhinney E, et al: Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. *Neurology*, 80(4): 400–5, 2013.
- McCluskey G, et al: Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. *Seizure*, 31: 311–5, 2021.
- Meador KJ, et al: In utero antiepileptic drug exposure: fetal death and malformations. *Neurology*, 67: 407–12, 2006.
- Meador K, et al: Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. *Epilepsy Res*, 81(1): 1–13, 2008.
- Meador KJ, et al: Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. *Lancet Neurol*, 12(3): 244–52, 2013.
- Meador KJ, et al: Effects of periconceptional folate on cognition in children of women with epilepsy: NEAD study. *Neurology*, 94(7): e729–e740, 2020. (a)
- Meador KJ, et al: Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. *Neurology*, 94: e1502–11, 2020. (b)
- Meng LC, et al: Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. *NEJM Evid*, 5(3): EVIDoa2500254, 2026.
- MHRA (Medicines and Healthcare products Regulatory Agency): Valproate: review of safety data and expert advice on

- management of risks. Public Assessment Report, 2023.
<https://www.gov.uk/government/publications/valproate-review-of-safety-data-and-expert-advice-on-management-of-risks> (Accessed at 2026/8)
- Moore E, et al: Pregnancy, baby, and childhood outcomes from using anti-seizure medication during pregnancy. *Commun Med (Lond)*, 6(1): 28, 2025.
- Morrow J, et al: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. *J Neurol Neurosurg Psychiatry*, 77: 193–8, 2006.
- Morrow JJ, et al: Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. *J Neurol Neurosurg Psychiatry*, 80(5): 506–11, 2009.
- Mostacci B, et al: Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study. *J Neurol Neurosurg Psychiatry*, 89: 223–4, 2018. (a)
- Mostacci B, et al: Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. *J Neurol Neurosurg Psychiatry*, 89(9): 983–8, 2018. (b)
- MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet*, 338(8760): 131–7, 1991.
- NAAPR (The North American Antiepileptic Drug Pregnancy Registry): Latest data. <https://www.aedpregnancyregistry.org/latest-data/> (Accessed at 2026/8)
- NICE: Epilepsies in children, young people and adults. NG217. Published 27 April 2022; last updated 05 August 2026. <https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults> (Accessed at 2026/8)
- Ogawa Y, et al: Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. *Epilepsy Res*, 8(1): 75–8, 1991.
- Olstad EW, et al: Paternal valproate use and impact of shared genetic susceptibility on child neurodevelopment. *Sci Rep*, 15(1): 39033, 2025.
- Omtzigt JG, et al: The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. *Neurology*, 42(4 Suppl 5): 119–25, 1992.
- Ornøy A, et al: Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. *Arch Dis Child*, 75: 517–20, 1996.
- Øyen N, et al: Maternal epilepsy and offspring's adult intelligence: a population-based study from Norway. *Epilepsia*, 48(9): 1731–38, 2007.
- Pack AM, et al: Teratogenesis, Perinatal, and Neurodevelopmental Outcomes

- After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. *Neurology*, 102(11): e209279, 2024.
- Palermo M, et al: Idiopathic Intracranial Hypertension in Pregnancy. A Systematic Review on Clinical Course, Treatments, Delivery and Maternal-Fetal Outcome. *Eur J Neurol*, 32(5): e70186, 2025.
- Patorno E, et al: Pregabalin use early in pregnancy and the risk of major congenital malformations. *Neurology*, 88: 2020–5, 2017.
- Peng A, et al: Periconceptional folic acid supplementation for women with epilepsy: A systematic review of the literature. *Epilepsy Behav*, 161: 110064, 2024.
- Pennell PB, et al: Differential effects of antiepileptic drugs on neonatal outcomes. *Epilepsy Behav*, 24(4): 449–56, 2012.
- Perucca P, et al: Epilepsy-pregnancy registries: An update. *Epilepsia*, 66(1): 47–59, 2025.
- Petersen JM, et al: Periconceptional folic acid and risk for neural tube defects among higher risk pregnancies. *Birth Defects Res*, 111(19): 1501–12, 2019.
- Pittschieler S, et al: Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. *J Neurol*, 255(12): 1926–31, 2008.
- Rasalam AD, et al: Characteristics of fetal anticonvulsant syndrome associated autistic disorder. *Dev Med Child Neurol*, 47: 551–5, 2005.
- Rauchenzauner M, et al: Generalized tonic-clonic seizures and antiepileptic drugs during pregnancy a matter of importance for the baby? *J Neurol*, 260(2): 484–8, 2013.
- Razaz N, et al: Association Between Pregnancy and Perinatal Outcomes Among Women With Epilepsy. *JAMA Neurol*, 74(8): 983–91, 2017.
- Razaz N, et al: Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis. *J Neurol Neurosurg Psychiatry*, jnnp-2025-337441, 2026.
- Reinisch JM, et al: In utero exposure to phenobarbital and intelligence deficits in adult men. *JAMA*, 274: 1518–25, 1995.
- Reis RM, et al: Altered sexual and reproductive functions in epileptic men taking carbamazepine. *J Sex Med*, 10(2): 493–9, 2013.
- Ren T, et al: Prenatal Carbamazepine Exposure and Academic Performance in Adolescents: A Population-Based Cohort Study. *Neurology*, 100: e728–38, 2023.
- Reynolds EH: Antiepileptic drugs, folate and one carbon metabolism revisited. *Epilepsy Behav*, 112: 107336, 2020.
- Rihtman T, et al: Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. *Reprod Toxicol*, 41: 115–25, 2013.
- Roth C, et al: Folic acid supplements in pregnancy and severe language delay in

- children. *JAMA*, 306(14): 1566 – 73, 2011.
- Rovet J, et al: Effects of maternal epilepsy on children ' s neurodevelopment. *Child Neuropsychology*, 1: 150–7, 1995.
- Sampaio AC, et al: Association of the Maternal Folic Acid Supplementation with the Autism Spectrum Disorder: A Systematic Review. *Rev Bras Ginecol Obstet*, 43(10): 775–81, 2021.
- Samrén EB, et al: Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. *Epilepsia*, 38(9): 981–90, 1997.
- Samrén EB, et al: Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol*, 46(5): 739–46, 1999.
- Schmidt RJ, et al: Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. *Am J Clin Nutr*, 96(1): 80–9, 2012.
- Scolnik D, et al: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. *JAMA*, 271: 767–70, 1994.
- Shallcross R, et al: Child development following in utero exposure: levetiracetam vs sodium valproate. *Neurology*, 76: 383–9, 2011.
- Shallcross R, et al: In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. *Neurology*, 82: 213–21, 2014.
- Smithells RW, et al: Apparent prevention of neural tube defects by periconceptional vitamin supplementation. *Arch Dis Child*, 56(12): 911–8, 1981.
- Steenweg-de Graaff J, et al: Maternal folate status in early pregnancy and child emotional and behavioral problems: the Generation R Study. *Am J Clin Nutr*, 95(6): 1413–21, 2012.
- Sun Y, et al: Timing of high-dose folic acid supplementation in the periconceptional period among women taking antiseizure medications and risk of major congenital anomalies: a target trial emulation. *J Neurol Neurosurg Psychiatry*, jnnp-2025-337395, 2026.
- Surén P, et al: Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. *JAMA*, 309(6): 570–7, 2013.
- Tallon E, et al: Reversible male infertility with valproate use: A review of the literature. *Epilepsy Behav Rep*, 16: 100446, 2021.
- Thomas SV, et al: Motor and mental development of infants exposed to antiepileptic drugs in utero. *Epilepsy Behav*, 13: 229–36, 2008.
- Thomas SV, et al: Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. *Epilepsia*, 58(2): 274–81, 2017.

- Thomas SV, et al: Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP). *Seizure*, 93: 127–32, 2021.
- Tisdale JE, et al: Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients. *Ther Drug Monit*, 14(5): 416–23, 1992.
- Tomson T, et al: Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. *Lancet Neurol*, 10(7): 609–17, 2011.
- Tomson T, et al: Teratogenic effects of antiepileptic drugs. *Lancet Neurol*, 11: 803–13, 2012.
- Tomson T, et al: Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. *Neurology*, 85(10): 866–72, 2015.
- Tomson T, et al: Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol*, 17(6): 530–38, 2018.
- Tomson T, et al: Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden. *J Neurol Neurosurg Psychiatry*, 91(9): 907–13, 2020. (a)
- Tomson T, et al: Global Survey of Guidelines for the Management of Epilepsy in Pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy. *Epilepsia Open*, 5(3): 366–370, 2020. (b)
- Vajda FJ, et al: Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. *Seizure*, 19(9): 558–61, 2010.
- Vajda FJ, et al: Dose dependence of fetal malformations associated with valproate. *Neurology*, 81(11): 999 – 1003, 2013.
- Vajda FJE, et al: Is carbamazepine a human teratogen? *J Clin Neurosci*, 23: 34–37, 2016.
- Vajda FJE, et al: Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register. *Seizure*, 65: 6–11, 2019.
- Vajda FJE, et al: Teratogenicity of zonisamide and other little-used antiseizure medications. *Seizure*, 117: 198 – 201, 2024. (a)
- Vajda FJE, et al: The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy. *Epilepsy Res*, 200: 107316, 2024. (b)
- Valera-Gran D, et al: Folic acid supplements during pregnancy and child psychomotor development after the first year of life. *JAMA Pediatr*, 168(11): e142611, 2014.
- Valera-Gran D, et al: Effect of maternal high dosages of folic acid supplements on neurocognitive development in children at 4-5 y of age: the prospective birth cohort Infancia y Medio

- Ambiente (INMA) study. *Am J Clin Nutr*, 106(3): 878–87, 2017.
- Van Marter LJ, et al: Neonatal Outcomes in the MONEAD Study of Pregnant Women with Epilepsy. *J Pediatr X*, 7: 100073, 2021.
- Vegrim HM, et al: Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy. *JAMA Neurol*, 79(11): 1130–38, 2022.
- Vegrim HM, et al: High-dose folic acid use and cancer risk in women who have given birth: A register-based cohort study. *Epilepsia*, 66(1): 75–88, 2025.
- Veiby G, et al: Pregnancy, delivery, and outcome for the child in maternal epilepsy. *Epilepsia*, 50: 2130–39, 2009.
- Veiby G, et al: Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. *Epilepsia*, 54: 1462–72, 2013.
- Veiby G, et al: Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. *J Neurol*, 261(3): 579–88, 2014.
- Viale L, et al: Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. *Lancet*, 386(10006): 1845–52, 2015.
- Viinikainen K, et al: Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. *Epilepsia*, 47(1): 186–92, 2006.
- Vinti D, et al: High versus standard dose folic acid supplementation for miscarriage prevention: systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol MFM*, 8(5): 101934, 2026.
- Wang Y, et al: Folic acid supplementation and dietary folate intake, and risk of preeclampsia. *Eur J Clin Nutr*, 69(10): 1145–50, 2015.
- WHO: Guideline: Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects. Geneva: World Health Organization; 2015. <https://www.who.int/publications/i/item/9789241549042> (Accessed at 2026/8)
- Wide K, et al: Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. *Epilepsia*, 41(7): 854–61, 2000. (a)
- Wide K, et al: Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. *Dev Med Child Neurol*, 42: 87–92, 2000. (b)
- Wide K, et al: Psychomotor development in preschool children exposed to antiepileptic drugs in utero. *Acta Paediatr*, 91: 409–14, 2002.
- Wiggs KK, et al: Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. *Neurology*, 95: e3232–e3240, 2020.
- Wilson RD, et al: The use of folic acid for the prevention of neural tube defects and

- other congenital anomalies. *J Obstet Gynaecol Can*, 25(11): 959–73, 2003.
- Wilson RD, et al: RETIRED: Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. *J Obstet Gynaecol Can*, 29(12): 1003–13, 2007.
- Wilson RD, et al: Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies. *J Obstet Gynaecol Can*, 37(6): 534–52, 2015.
- Wilson RD, et al: Guideline No. 427: Folic Acid and Multivitamin Supplementation for Prevention of Folic Acid-Sensitive Congenital Anomalies. *J Obstet Gynaecol Can*, 44(6): 707 – 719.e1, 2022.
- Winterfeld U, et al: Pregnancy outcome following maternal exposure to pregabalin may call for concern. *Neurology*, 86: 2251–7, 2016.
- Wood AG, et al: Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. *Epilepsia*, 56: 1047–55, 2015.
- Xiaotian X, et al: Effects of antiepileptic drugs on reproductive endocrine function, sexual function and sperm parameters in Chinese Han men with epilepsy. *J Clin Neurosci*, 20(11): 1492–7, 2013.
- Xu SC, et al: Exposure to anti-seizure medication during pregnancy and the risk of autism and ADHD in offspring: a systematic review and meta-analysis. *Front Neurol*, 15: 1440145, 2024.
- Yan J, et al: Association between Duration of Folic Acid Supplementation during Pregnancy and Risk of Postpartum Depression. *Nutrients*, 9(11): 1206, 2017.
- Yan Y, et al: Exposure to Excess Phenobarbital Negatively Influences the Osteogenesis of Chick Embryos. *Front Pharmacol*, 7: 349, 2016.
- Yerby MS, et al: Male infertility: possible association with valproate exposure. *Epilepsia*, 40(4): 520–1, 1999.
- Zhang Q, et al: Effect of folic acid supplementation on preterm delivery and small for gestational age births: A systematic review and meta-analysis. *Reprod Toxicol*, 67: 35–41, 2017.
- Zhong TW, et al: Effect of carbamazepine combined with folic acid in treatment of epilepsy during pregnancy and its impact on maternal and infantile outcomes. *Maternal and Child Health Care of China*, 32(17): 4085–89, 2017.
- 加藤昌明：バルプロ酸のリスク．*精神科*, 35(2)：146–54, 2019.
- 厚生労働省：「日本人の食事（2025 年版）」策定検討会：報告書．2024 年 10 月．https://www.mhlw.go.jp/stf/newpage_44138.html (Accessed at 2026/8)
- 近藤厚生：神経管閉鎖障害：葉酸摂取による予防．*ビタミン*, 92 (1)：1-17, 2018.
- 篠崎圭子：若年女性の血中葉酸値と遺伝子

多型の調査. 厚生労働省科学研究費補助金難治性疾患克服研究事業 (No.23163901) 近藤厚生:総括研究年度終了報告書. 2012: 58-63.

日本神経学会監修:「てんかん診療ガイドライン」作成委員会編: CQ13-3 葉酸は補充すべきか. てんかん診療ガイドライン 2018. 医学書院. 2018, p.138.

日本精神神経学会・日本産科婦人科学会: 精神疾患を合併した, 或いは合併の可能性のある妊産婦診療ガイド 各論編 9.

てんかん. 精神神経学雑誌, 第 124 巻 (2022 年) 別冊 Web 版.

https://www.jspn.or.jp/modules/advocacy/index.php?content_id=87 (accessed 2026-08-20) .

日本てんかん学会JRAP 委員会: 妊娠と抗てんかん薬に関する多施設共同前向き観察研究 (JRAP) 経過報告. てんかん研究, 44(1): 40-45, 2026.

第 4 章

Anderson PO, et al: A Review of Adverse Reactions in Infants From Medications in Breastmilk. Clin Pediatr (Phila), 55(3): 236-44, 2016.

Berlin M, et al: Therapeutic levetiracetam monitoring during pregnancy: "mind the gap". Ther Adv Chronic Dis, 10: 2040622319851652, 2019.

Birnbaum AK, et al: Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy. JAMA Neurol, 77(4): 441-50, 2020.

Cappellari AM, et al: Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring. Ther Drug Monit, 37(3): 285-7, 2015.

Clobazam. LactMed ® .
<https://www.ncbi.nlm.nih.gov/books/NBK501854/> (Accessed at 2026/8)

Clonazepam. LactMed ® .

<https://www.ncbi.nlm.nih.gov/books/NBK501209/> (Accessed at 2026/8)

Davanzo R, et al: Antiepileptic drugs and breastfeeding. Ital J Pediatr, 39: 50, 2013.

de Haan GJ, et al: Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology, 63: 571-3, 2004.

Diazepam. LactMed ® .
<https://www.ncbi.nlm.nih.gov/books/NBK501214/> (Accessed at 2026/8)

Ding Y, et al: Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. Brain Behav, 9(7): e01315, 2019.

Ethosuximide. LactMed ® .
<https://www.ncbi.nlm.nih.gov/books/NBK501219/> (Accessed at 2026/8)

Fallik N, et al: Therapeutic drug monitoring in pregnancy: Levetiracetam. Epilepsia, 65

- (5): 1285–1293, 2024.
- Fotopoulou C, et al: Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. *Epilepsy Res*, 85: 60–4, 2009.
- Gardner I, et al: Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy. *AAPS J*, 27(1): 40, 2025.
- Goo Y, et al: Dose Monitoring of Lamotrigine Monotherapy in Pregnancy: Are Pregnant Women with Epilepsy Currently Optimally Managed? A Systematic Review. *Ther Drug Monit*, 46(2): 181–94, 2024.
- Hägg S, et al: Anticonvulsant use during lactation. *Drug Saf*, 22(6): 425–40, 2000.
- Hahn W, et al: Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature. *Neurol Res Pract*, 6(1): 17, 2024.
- Hale TW, et al: *Hale's Medications & Mother's Milk 2025-2026*. 21st ed. Springer Publishing Company, 2025.
- Hovenga CA, et al: Antiepileptic drug therapy in pregnancy II: fetal and neonatal exposure. *Int Rev Neurobiol*, 83: 241–58, 2008.
- Karanam A, et al: Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy. *Pharmacotherapy*, 45(1): 33–42, 2025.
- Lamotrigine. LactMed ® . <https://www.ncbi.nlm.nih.gov/books/NBK501268/> (Accessed at 2026/8).
- Landmark CJ, et al: Pharmacokinetic variability of valproate during pregnancy Implications for the use of therapeutic drug monitoring. *Epilepsy Res*, 141: 31–37, 2018.
- Landmark CJ, et al: Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation. *Epileptic Disord*, 23(2): 426–31, 2021.
- Lutz UC, et al: Oxcarbazepine treatment during breast-feeding: a case report. *J Clin Psychopharmacol*, 27(6): 730–2, 2007.
- Meador KJ, et al: Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. *JAMA Pediatr*, 168(8): 729–36, 2014.
- Merlob P, et al: Antiepileptics. In: Schaefer C, Peters P, Miller RK, eds. *Drugs During Pregnancy and Lactation: Treatment Options & Risk Assessment*. 3rd ed. Academic Press, 2015.
- Nordmo E, et al: Severe apnea in an infant exposed to lamotrigine in breast milk. *Ann Pharmacother*, 43(11): 1893–7, 2009.
- Patsalos PN, et al: Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. *Epilepsia*, 58(7): 1234–43, 2017.
- Pennell PB, et al: Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. *Neurology*, 70(22 Pt 2): 2130–6, 2008.
- Pennell PB, et al: Antiseizure Medication

- Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. *JAMA Neurol*, 79(4): 370–9, 2022.
- Pennell PB, et al: Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. *Neurology*, 106(2): e214483, 2026.
- Petrenaite V, et al: Individual changes in lamotrigine plasma concentrations during pregnancy. *Epilepsy Res*, 65: 185–8, 2005.
- Petrenaite V, et al: UGT polymorphisms and lamotrigine clearance during pregnancy. *Epilepsy Res*, 140: 199–208, 2018.
- Phenobarbital. *LactMed* ® .
<https://www.ncbi.nlm.nih.gov/books/NBK501272/>
 (Accessed at 2026/8)
- Piontek CM, et al: Serum valproate levels in 6 breastfeeding mother-infant pairs. *J Clin Psychiatry*, 61(3): 170–2, 2000.
- Polepally AR, et al: Model-based lamotrigine clearance changes during pregnancy: clinical implication. *Ann Clin Transl Neurol*, 1(2): 99–106, 2014.
- Primidone. *LactMed* ® .
<https://www.ncbi.nlm.nih.gov/books/NBK501249/> (Accessed at 2026/8)
- Reimers A, et al: Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. *Epilepsy Res*, 94(3): 198–205, 2011.
- Reisinger TL, et al: Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. *Epilepsy Behav*, 29(1): 13–8, 2013.
- Sabers A: Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. *Acta Neurol Scand*, 126(1): e1–4, 2012.
- Schelhaas M, et al: Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. *Neurology*, 100(2): e172–81, 2023.
- Schmidt CT, et al: Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. *Prog Neuropsychopharmacol Biol Psychiatry*, 124: 110733, 2023.
- Soussan C, et al: Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. *Eur J Clin Pharmacol*, 70(11): 1361–6, 2014.
- Stahl MM, et al: Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. *J Pediatr*, 130(6): 1001–3, 1997.
- Tomson T, et al: Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. *Epilepsia*, 54(3): 405–14, 2013.
- Tomson T, et al: Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force. *Epileptic Disord*, 24(6): 1020–32, 2022.
- Topiramate. *LactMed* ® .

- <https://www.ncbi.nlm.nih.gov/books/NBK501259/> (Accessed at 2026/8)
- Towers CV, et al: Briggs Drugs in Pregnancy and Lactation. 13th ed. Wolters Kluwer Health, 2025.
- Valproate. LactMed®. <https://www.ncbi.nlm.nih.gov/books/NBK501274/> (Accessed at 2026/8)
- Vazquez B, et al: Perampanel and pregnancy. *Epilepsia*, 62(3): 698–708, 2021.
- Veiby G, et al: Epilepsy and recommendations for breastfeeding. *Seizure*, 28: 57–65, 2015.
- Voinescu PE, et al: Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. *Neurology*, 91(13): e1228–36, 2018.
- Westergren T, et al: Probable topiramate-induced diarrhea in a 2-month-old breast-fed child - A case report. *Epilepsy Behav Case Rep*, 2: 22–3, 2014.
- Westin AA, et al: Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. *Seizure*, 17: 192–8, 2008.
- Yalçın HT, et al: Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMed®. *Pharmaceuticals (Basel)*, 17(12): 1654, 2024.
- Zonisamide. LactMed®. <https://www.ncbi.nlm.nih.gov/books/NBK501266/> (Accessed at 2026/8)
- 伊藤真也：薬剤の母乳移行と乳児の薬剤曝露。薬物治療コンサルテーション 妊娠と授乳。改訂第4版。南山堂，2025，p.53.
- 伊藤直樹：抗不安薬。薬物治療コンサルテーション 妊娠と授乳。改訂第4版。南山堂，2025，pp.425–27.
- 加藤昌明：調剤と情報，25：1060–77，2019
- 日本神経学会監修：「てんかん診療ガイドライン」作成委員会編：CQ13-7 抗てんかん薬服用中の授乳は可能か。てんかん診療ガイドライン 2018。医学書院，2018，pp.142–3.
- 日本腎臓学会学術委員会ほか：腎疾患患者の妊娠診療ガイドライン 2017。診断と治療社，2017.
- 日本精神神経学会・日本産科婦人科学会監修：精神疾患を合併した，或いは可能性のある妊産婦の診療ガイド 各論編 9 てんかん。精神誌，124：別冊 Web 版，2022。
https://www.jspn.or.jp/modules/advocacy/index.php?content_id=87 (accessed 2026-08-20) .
- 日本精神神経学会・日本産科婦人科学会監修：こころの不調や病気と妊娠・出産のガイド（一般の方むけ）。
https://www.jspn.or.jp/modules/forpublic/index.php?content_id=71 (Accessed at 2026/8)

第5章

- Abbasi F, et al: Effects of menopause on seizures in women with epilepsy. *Epilepsia*, 40(2):205–10, 1999.

- Andersen NB, et al: Impaired bone health as a co-morbidity of epilepsy. *Best Pract Res Clin Rheumatol*, 36(3): 101755, 2022.
- Arora E, et al: Impact of antiepileptic drugs on bone health: Need for monitoring, treatment, and prevention strategies. *J Family Med Prim Care*, 5(2): 248–53, 2016.
- Babunovska M, et al: Fractures in people with epilepsy: A nationwide population-based cohort study. *Epilepsia Open*, 8(3): 1028–37, 2023.
- Beniczky SA, et al: Bone mineral density in adult patients treated with various antiepileptic drugs. *Seizure*, 21(6): 471–2, 2012.
- Carbone LD, et al: Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). *J Bone Miner Res*, 25(4): 873–81, 2010.
- Carvalho V, et al: Sex steroid hormones and epilepsy: Effects of hormonal replacement therapy on seizure frequency of postmenopausal women with epilepsy-A systematic review. *Eur J Neurol*, 30(9): 2884–98, 2023.
- Chandrasekaran V, et al: Anticonvulsant use and bone health in a population-based study of men and women: cross-sectional data from the Geelong Osteoporosis Study. *BMC Musculoskelet Disord*, 22(1): 172, 2021. (a)
- Chandrasekaran V, et al: Anticonvulsant use and fracture: a case-control study. *J Musculoskelet Neuronal Interact*, 21(3): 422–8, 2021. (b)
- Chen FP, et al: Relationship Between Serum 25-Hydroxyvitamin D and Bone Mineral Density, Fracture Risk, and Bone Metabolism in Adults With Osteoporosis/Fractures. *Endocr Pract*, 30(7): 616–23, 2024.
- DeShazo SJ, et al: Phenytoin is associated with increased risk of osteoporosis and fragility fractures in adult epileptic patients. *J Bone Miner Metab*, 42(1): 69–76, 2024.
- El-Haggar SM, et al: Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients. *Arq Neuropsiquiatr*, 76(7): 452–8, 2018.
- Erel T, et al: Epilepsy and menopause. *Arch Gynecol Obstet*, 284(3): 749–55, 2011.
- Farhat G, et al: Effect of antiepileptic drugs on bone density in ambulatory patients. *Neurology*, 58(9): 1348–53, 2002.
- FRAXplus. <https://www.fraxplus.org/> (Accessed at 20267/5)
- Fernandez H, et al: Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. *Epilepsia*, 59(4): 885–96, 2018.
- Gaete PV, et al: Antiseizure Medications and Bone Health. *Neurol Ther*, 14(5): 1827–44, 2025.
- Gascon-Barré M, et al: Effect of increasing doses of phenytoin on the plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations. *J Am Coll Nutr*, 3(1): 45–50, 1984.
- Guo Y, et al: Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients

- with epilepsy. *Epilepsy Behav*, 113: 107489, 2020.
- Hahn TJ, et al: Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration. *Calcif Tissue Int*, 27(1): 13–8, 1979.
- Hakami T, et al: Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health. *Calcif Tissue Int*, 98(6): 556–65, 2016.
- Harden CL, et al: The effect of menopause and perimenopause on the course of epilepsy. *Epilepsia*, 40(10): 1402–7, 1999.
- Harden CL, et al: Seizure frequency is associated with age at menopause in women with epilepsy. *Neurology*, 61(4): 451–5, 2003.
- Harden CL, et al: Hormone replacement therapy in women with epilepsy: a randomized, doubleblind, placebo-controlled study. *Epilepsia*, 47(9): 1447–51, 2006.
- Harden CL: Hormone replacement therapy: will it affect seizure control and AED levels? *Seizure*, 17(2): 176–80, 2008.
- Heo K, et al: The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. *Epilepsia*, 52(10): 1884–9, 2011.
- Holick MF: Revisiting Vitamin D Guidelines: A Critical Appraisal of the Literature. *Endocr Pract*, 30(12): 1227–41, 2024.
- Jetté N, et al: Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. *Arch Neurol*, 68(1): 107–12, 2011.
- Jiang X, et al: Effects of levetiracetam on bone mineral density and bone metabolism in patients with epilepsy: A systematic review and meta-analysis. *Epilepsy Behav*, 158: 109925, 2024.
- Josephson CB, et al: Independent Associations of Incident Epilepsy and Enzyme-Inducing and Non-Enzyme-Inducing Antiseizure Medications With the Development of Osteoporosis. *JAMA Neurol*, 80(8): 843–50, 2023.
- Khodabakhshi A, et al: Vitamin D status, including serum levels and sun exposure are associated or correlated with bone mass measurements diagnosis, and bone density of the spine. *BMC Nutr*, 9(1): 48, 2023.
- Klein P, et al: Premature ovarian failure in women with epilepsy. *Epilepsia*, 42(12): 1584–9, 2001.
- Koo DL, et al: Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. *Epilepsy Res*, 104(1-2): 134–9, 2013.
- Koo DL, et al: Effects of zonisamide monotherapy on bone health in drug-naïve epileptic patients. *Epilepsia*, 61(10): 2142–9, 2020.
- Lapi F, et al: Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. *Bone*, 50(1): 85–90, 2012.
- Leonard H, et al: Valproate and risk of fracture

- in Rett syndrome. *Arch Dis Child*, 95(6): 444–8, 2010.
- Liu A, et al: Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy. *Exp Ther Med*, 20(4): 3687–94, 2020.
- Liu Y, et al: Vitamin D content and prevalence of vitamin D deficiency in patients with epilepsy: a systematic review and meta-analysis. *Front Nutr*, 11: 1439279, 2024.
- MacLaughlin J, Holick MF: Aging decreases the capacity of human skin to produce vitamin D₃. *J Clin Invest*, 76(4): 1536–8, 1985.
- McAuley JW, et al: Characterization and health risk assessment of postmenopausal women with epilepsy. *Epilepsy Behav*, 1(5): 353–5, 2000.
- Mintzer S, et al: Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. *Epilepsia*, 47(3): 510–5, 2006.
- Miziak B, et al: An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs. *Expert Opin Drug Saf*, 18(8): 679–89, 2019.
- Nicholas JM, et al: Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. *Seizure*, 22(1): 37–42, 2013.
- Pack AM, et al: Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. *Neurology*, 70(18): 1586–93, 2008.
- Pedrerá JD, et al: Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. *Eur J Clin Invest*, 30(10): 895–9, 2000.
- Persson HB, et al: Risk of extremity fractures in adult outpatients with epilepsy. *Epilepsia*, 43(7): 768–72, 2002.
- Phabphal K, et al: Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. *Epilepsia*, 54(6): e94–8, 2013.
- Pisa F, et al: Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. *Clin Epidemiol*, 13: 295–307, 2021.
- Reimers A: Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study. *Epilepsia*, 58(1): e6–9, 2017.
- Rossouw JE, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*, 288(3): 321–33, 2002.
- Salimipour H, et al: Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest. *J Nucl Med Technol*, 41(3): 208–11, 2013.
- Schousboe JT, et al: Liver enzyme inducing anticonvulsant drug use is associated with prevalent vertebral fracture. *Osteoporos Int*, 34(10): 1793–8, 2023.

- Shen C, et al: Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. *Bone*, 64: 246–53, 2014.
- Shiek Ahmad B, et al: Falls and fractures in patients chronically treated with antiepileptic drugs. *Neurology*, 79(2): 145 – 51, 2012.
- Singla S, et al: Bone Health in Patients with Epilepsy: A Community-based Pilot Nested Case-control Study. *Ann Indian Acad Neurol*, 20(4): 367–71, 2017.
- Sommer IEC, et al: Do women need a change in dose of prescription drugs with onset of menopause? Time to find out. *BMC Med*, 23(1): 411, 2025.
- Souverein PC, et al: Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. *Epilepsia*, 46(2): 304–10, 2005.
- Souverein PC, et al: Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. *Neurology*, 66(9): 1318–24, 2006.
- Suljic EM, et al: Effect of Long-term Carbamazepine Therapy on Bone Health. *Med Arch*, 72(4): 262–6, 2018.
- Sveinsson O, et al: Epilepsy and menopause: potential implications for pharmacotherapy. *Drugs Aging*, 31(9): 671–5, 2014.
- Tomson T, et al: Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. *Epilepsy Behav*, 19(1): 86–8, 2010.
- Tsiropoulos I, et al: Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. *Epilepsia*, 49(12): 2092–9, 2008.
- Vestergaard P, et al: Fracture risk is increased in epilepsy. *Acta Neurol Scand*, 99(5): 269–75, 1999.
- Vestergaard P, et al: Fracture risk associated with use of antiepileptic drugs. *Epilepsia*, 45(11): 1330–7, 2004.
- Vestergaard P: Epilepsy, osteoporosis and fracture risk - a meta-analysis. *Acta Neurol Scand*, 112(5): 277–86, 2005.
- Watson KC, et al: Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. *Womens Health Issues*, 16(6): 346–52, 2006.
- Wegner I, et al: Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. *Neurology*, 73(17): 1388–93, 2009.
- Wegner I, et al: The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. *Epilepsy Behav*, 29(1): 217–21, 2013.
- Whitney DG, et al: Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy. *Epilepsia*, 62(9): 2180–9, 2021.
- Yasui T, et al: Factors associated with premature ovarian failure, early menopause and earlier onset of menopause in Japanese women. *Maturitas*, 72(3): 249–55, 2012.
- Yu M, et al: Effects of perampanel on bone

- health in adult patients with epilepsy. *Epilepsia Open*, 10(3): 822–30, 2025.
- Zhang X, et al: Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis. *J Int Med Res*, 48(3): 300060520902608, 2020.
- Zhong R, et al: Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis. *Front Neurol*, 10: 1171, 2019.
- 網塚憲生: 講座 骨の細胞における組織学的・微細構造学的所見, 2015. 日本顕微鏡学会 . https://microscopy.or.jp/jsm/wp-content/uploads/publication/kenbikyo/50_3/pdf/50-3-191.pdf (Accessed at 2026/8)
- 環境省: 紫外線環境保健マニュアル 2020 巻末資料 2 <https://www.env.go.jp/content/900410650.pdf> (Accessed at 2026/8)
- 気象庁: 〈防災情報〉紫外線情報 (分布図) <https://www.data.jma.go.jp/env/uvindex/index.html?elem=0&area=0&lat=34.2&lng=138.53&zoom=5> (Accessed at 2026/8)
- 国立環境研究所: 環境儀 No.79 ビタミン D とは? <https://www.nies.go.jp/pr/publications/kankyogi/79/column1.html> (Accessed at 2026/8)
- 国立環境研究所: 環境儀 No.79 HP からの最適な日光照射時間の提供 . <https://www.nies.go.jp/pr/publications/kankyogi/79/column5.html> (Accessed at 2026/8)
- 骨粗鬆症の予防と治療ガイドライン作成委員会: 骨粗鬆症の予防と治療ガイドライン 2025 年版, 2025. http://www.josteo.com/data/publications/guideline/2025_01.pdf (Accessed at 2026/8)
- 玉田太朗ほか: 本邦女性の閉経年齢. *日本産科婦人科学会雑誌*, 47(9): 947–52, 1995.
- 日本食品分析センター: ビタミン D 代謝物について～25-ヒドロキシビタミン D を中心に . 最新情報 . 2011; 3-32. https://www.jfrl.or.jp/storage/file/news_vol3_no32.pdf (Accessed at 2026/8)
- 日本女性医学学会監修: ホルモン補充療法ガイドライン 2025 年度版, 2025.